ME3221, a surmountable angiotensin AT1-receptor antagonist, prevents hypertensive complications in aged stroke-prone spontaneously hypertensive rats

Japanese Journal of Pharmacology

Volumn 71, Issue 1, 1996, Pages 39-49

  Nagura, Jun ^a   Hui, Chen ^a   Yamamoto, Mikio ^a   Yasuda, Sumie ^a   Abe, Mitsuhiro ^a   Hachisu, Mitsugu ^a   Konno, Fukio ^a  

^a MEIJI SEIKA KAISHA LTD   (Japan)

Author keywords

Angiotensin AT1 receptor antagonist; ME3221; Stroke prone spontaneously hypertensive rat

Indexed keywords

3 METHOXY 2,6 DIMETHYL 4 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHOXY]PYRIDINE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ENALAPRIL; LOSARTAN; N ACETYL BETA GLUCOSAMINIDASE;

AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DRUG STRUCTURE; ENZYME ACTIVITY; HEART VENTRICLE HYPERTROPHY; HEART WEIGHT; HISTOLOGY; HYPERTENSION; KIDNEY MASS; MALE; MORTALITY; NONHUMAN; ORAL DRUG ADMINISTRATION; PLEURA EFFUSION; PROTEIN URINE LEVEL; PROTEINURIA; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; STROKE; SURVIVAL; SYSTOLIC BLOOD PRESSURE; URINE VOLUME;

EID: 0029882588     PISSN: 00215198     EISSN: None     Source Type: Journal    
DOI: 10.1254/jjp.71.39     Document Type: Article

References (30)

1. Okamoto K, Yamori Y and Nagaoka A: Establishment of the stroke-prone spontaneously hypertensive rat (SHR). Circ Res 34-35, Supp 1, 143-153 (1974)
2. Wong PC, Price WA, Chiu AT, Duncia JV, Carini DJ, Wexler RR, Johnson AL and Timmermans PBMWM: Nonpeptide angiotensin II receptor antagonists. IX. Antihypertensive activity in rats of DuP753, an orally active antihypertensive agent. J Pharmacol Exp Ther 252, 726-732 (1990)
3. Wong PC, Price WA Jr, Chiu AT, Duncia JV, Carini DJ, Wexler RR, Johnson AL and Timmermans PBMWM: Hypertensive action of DuP753, an angiotensin II antagonist, in spontaneously hypertensive rats. Hypertension 15, 459-468 (1990)
4. Camargo MJF, von Lutterotti N, Pecker MS, James GD, Timmermans PBMWM and Laragh JH: DuP753 increases survival in spontaneously hypertensive stroke-prone rats fed a high sodium diet. Am J Hypertens 4, Pt 2, 341S-345S (1991)
5. Stier CT Jr, Sim G, Mahboubi K, Shen W, Levine S and Chander PN: Prevention of stroke and hypertensive renal disease by the angiotensin II receptor antagonist DuP753 in salt-loaded stroke-prone SHR, In Current Advances in ACE Inhibition 2, pp 252-255, Churchill Livingstone, London (1991)
6. Fornes P, Richer C, Vacher E, Bruneval P and Giudicelli JF: Losartan's protective effects in stroke-prone spontaneously hypertensive rats persist durably after treatment withdrawal. J Cardiovasc Pharmacol 22, 305-313 (1993)
7. Wong PC, Price WA, Chiu AT, Duncia JV, Carini DJ, Wexler RR, Johnson AL and Timmermans PBMWM: Nonpeptide angiotensin II receptor antagonists. XI. Pharmacology of EXP3174: An active metabolite of DuP753, an orally active antihypertensive agent. J Pharmacol Exp Ther 255, 211-217 (1990)
8. Wong PC and Timmermans PBMWM: Nonpeptide angiotensin II receptor antagonists: Insurmountable angiotensin II antagonism of EXP3892 is reversed by the surmountable antagonist DuP753. J Pharmacol Exp Ther 258, 49-57 (1991)
9. Lacourcière Y, Lefebvre J, Snavely DP, Faison EP and Nelson EB: Effects of modulators of the renin angiotensin aldosterone system on cough. J Hypertens 12, Supp 3, S67 (1994)
10. Arakawa K: Losartan: Clinical pharmacology profile and potential benefits. Abstract in the Satellite Symposium of 15th International Society of Hypertension. All antagonist: a new class for the treatment of hypertension, p 10 (1994)
11. Nelson EB and Goldberg MR: Clinical aspects of losartan. Abstract in the Satellite Symposium of 15th International Society of Hypertesion. All antagonist: a new class for the treatment of hypertension, p 20 (1994)
12. Kawano K, Yasuda S, Fujishima K, Nagura J, Hachisu M and Konno F: In vitro profile of ME3221, a novel nonpeptide angiotensin II (AII) receptor antagonist. Jpn J Pharmacol 64, Supp I, 331P (1994)
13. Nagura J, Fujishima K, Kawano K, Yasuda S, Hachisu M and Konno F: Pharmacological profile of ME3221, a novel angiotensin II (AII) receptor antagonist. J Hypertens 12, Supp 3, S99 (1994)
14. Yasuda S, Chen Hui, Fujishima K, Kawano K, Nagura J, Hachisu M and Konno F: In vivo pharmacological profile of ME3221, a novel angiotensin II (AII) receptor antagonist. Jpn J Pharmacol 64, Supp I, 331P (1994)
15. Nagura J, Yasuda S, Fujishima K, Yamamoto M, Chen Hui, Kawano K, Katano K, Ogino H, Hachisu M and Konno F: Pharmacological profile of ME3221, a novel angiotensin II receptor antagonist. Eur J Pharmacol 274, 201-211 (1995)
16. Nagura J, Yamamoto M, Chen Hui, Yasuda S, Hachisu M and Konno F: Protective effects of ME3221 on hypertensive complications and lifespan in salt-loaded stroke-prone spontaneously hypertensive rats. Clin Exp Pharmacol Physiol (in press)
17. Stier CT Jr, Benter IF, Ahmad S, Zuo H, Selig N, Roethel S, Levine S and Itskovitz HD: Enalapril prevents stroke-prone spontaneously hypertensive rats. Hypertension 13, 115-121 (1989)
18. Stier CT Jr, Chander P, Gutstein WH, Levine S and Itskovitz HD: Therapeutic benefit of captopril in salt-loaded stroke-prone spontaneously hypertensive rats in independent of hypotensive effect. Am J Hypertens 4, 680-687 (1991)
19. Nagaoka A, Iwatsuka H, Suzuki Z and Okamoto K: Genetic predisposition to stroke in spontaneously hypertensive rats. Am J Physiol 230, 1354-1359 (1976)
20. Nagaoka A: Pharmacological prevention of cerebral stroke in stroke-prone spontaneously hypertensive rats. J Hypertens 4, Supp 3, 8523-8525 (1986)
21. Nagaoka A, Shino A and Shibota M: Implication of renal perfusion pressure in stroke of spontaneously hypertensive rats. Am J Physiol 238, H317-H324 (1980)
22. Blantz RC, Konnen KS and Tucker BJ: Angiotensin It effects upon the glomerular microcirculation and ultrafiltration coefficient of the rat. J Clin Invest 57, 419-434 (1976)
23. Anderson S, Rennke HG and Brenner BM: Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest 77, 1993-2000 (1986)
24. Keilani T, Schneter WA, Levin ML and Batlle DC: Improvement of lipid abnormalities associated with proteinuria using fosinopril, an angiotensin-converting enzyme inhibitor. Ann Intern Med 118, 246-254 (1993)
25. de Zeeuw D: Effects of losartan in patients with renal disease. Abstract in the Satellite Symposium of 15th International Society of Hypertension. All antagonist: a new class for the treatment of hypertension, p 14 (1994)
26. Katoh Y, Komuro I, Shibasaki Y, Yamaguchi H and Yazaki Y: Angiotensin II induces hypertrophy and oncogene expression in cultured rat heart myocytes. Circulation 80, Supp II, II-450 (1989)
27. Campbell WB and Jackson EK: Modulation of adrenergic transmission by angiotensins in the perfused rat mesentery. Am J Physiol 236, H211-H217 (1979)
28. Zimmerman BG, Sybertz EJ and Wong PC: Interaction between sympathetic and renin-angiotensin system. J Hypertens 2, 581-587 (1984)
29. Schunkert H, Dzau VJ, Tang SS, Hirsch AT, Apstein CS and Lorell BH: Increased rat cardiac angiotensin converting enzyme activity and mRNA expression in pressure overload left ventricular hypertrophy. J Clin Invest 86, 1913-1920 (1990)
30. Baker KM, Chernin MI, Wixson SK and Aceto JF: Renin-angiotensin system involvement in pressure-overload cardiac hypertrophy in rats. Am J Physiol 259, H324-H332 (1990)